JP2017501148A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501148A5
JP2017501148A5 JP2016538783A JP2016538783A JP2017501148A5 JP 2017501148 A5 JP2017501148 A5 JP 2017501148A5 JP 2016538783 A JP2016538783 A JP 2016538783A JP 2016538783 A JP2016538783 A JP 2016538783A JP 2017501148 A5 JP2017501148 A5 JP 2017501148A5
Authority
JP
Japan
Prior art keywords
protein
mixture
conjugation
chemical moiety
reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016538783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501148A (ja
JP6603662B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077777 external-priority patent/WO2015086853A1/en
Publication of JP2017501148A publication Critical patent/JP2017501148A/ja
Publication of JP2017501148A5 publication Critical patent/JP2017501148A5/ja
Application granted granted Critical
Publication of JP6603662B2 publication Critical patent/JP6603662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016538783A 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法 Active JP6603662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13197150 2013-12-13
EP13197150.9 2013-12-13
PCT/EP2014/077777 WO2015086853A1 (en) 2013-12-13 2014-12-15 Method for thioether conjugation of proteins

Publications (3)

Publication Number Publication Date
JP2017501148A JP2017501148A (ja) 2017-01-12
JP2017501148A5 true JP2017501148A5 (enExample) 2018-01-25
JP6603662B2 JP6603662B2 (ja) 2019-11-06

Family

ID=49765887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538783A Active JP6603662B2 (ja) 2013-12-13 2014-12-15 タンパク質のチオエーテルコンジュゲーション方法

Country Status (6)

Country Link
US (1) US11219690B2 (enExample)
EP (1) EP3079722B1 (enExample)
JP (1) JP6603662B2 (enExample)
CN (1) CN106068127B (enExample)
ES (1) ES2869309T3 (enExample)
WO (1) WO2015086853A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
JP7504025B2 (ja) * 2017-08-04 2024-06-21 アムジエン・インコーポレーテツド Cys-mabのコンジュゲーション方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042175A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2004101597A2 (en) 2003-05-13 2004-11-25 Frutarom Ltd. Methods for the reduction of disulfide bonds
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
US20090062509A1 (en) * 2006-03-16 2009-03-05 Aldo Cagnolini Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
US8586532B2 (en) 2007-08-24 2013-11-19 Novo Nordisk Healthcare A/G Method for selectively modifying a protein via transglutaminase catalyzed reaction
MX345736B (es) * 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
CA2836478A1 (en) 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
TR201903707T4 (tr) * 2011-11-02 2019-04-22 Hoffmann La Roche Aşırı yükleme ve elüsyon kromatografisi.
CN103087183A (zh) * 2013-01-17 2013-05-08 南京邮电大学 一种光激发蛋白质中二硫键还原得到自由巯基的方法

Similar Documents

Publication Publication Date Title
JP2017501148A5 (enExample)
Leichner et al. Thiolated polymers: Bioinspired polymers utilizing one of the most important bridging structures in nature
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
JP2015519313A5 (enExample)
MX2022006511A (es) Polipeptidos efectores de la sub-unidad a de la toxina shiga, andamiajes de los efectores de la toxina shiga, y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
CA2846598C (en) Treatment of degenerative joint disease
BRPI0406800B1 (pt) Dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
Da Silva et al. Partitioning of glycomacropeptide in aqueous two-phase systems
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
BR112013022252B1 (pt) método para isolar osteopontina utilizando alimentos concentrados
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
CN106928320A (zh) 一种合成Etelcalcetide的方法
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
RU2016107873A (ru) Пептиды
JP6603662B2 (ja) タンパク質のチオエーテルコンジュゲーション方法
NZ707895A (en) Formulation for bispecific t-cell engagers (bites)
Gerling-Driessen et al. Exploiting Oligo (amido amine) backbones for the multivalent presentation of coiled-coil peptides
KR20110136504A (ko) Rage 수용체 표적 펩타이드에 약물을 결합시킨 것을 특징으로 하는 약물 복합체
BR112012032364B1 (pt) Succinilato de caseína férrica e método para a preparação do mesmo
CA2908475C (en) Use of antibody-urease conjugates for diagnostic and therapeutic purposes
AU2020399030A1 (en) Calcium-sensing receptor agonist compound and application thereof
JP2019503994A5 (enExample)
CA2794217C (en) Thiosulfonate compound, reversible cationization agent for protein and/or peptide, and method for solubilization
BR112023023830A2 (pt) Composições, método para preparar as referidas composições, proteína mutante cralbp sensível a redox e sequência de ácido nucleico que codifica a mesma
JPWO2017154869A1 (ja) 変異型ヒトエリスロポエチンの製造方法